Insider trade report
Open the filing on sec.gov
Iovance Biotherapeutics, Inc. (IOVA)
Nasdaq: IOVA · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2008
The companyfiscal 2025, as filed
Revenue$264M+60.6%
Net income-$391M-5.1%
Earnings per share$-1.09+14.8%
Operating cash flow-$302M+14.3%
Cash$163M+41.0%
Debtn/a
Shareholders’ equity$699M-1.7%
Shares, diluted357.3M+23.3%
Return on equity-56.0%
The recordfrom its filings
Filings in 202672
Newest filingNov 12 · 4
Annual reportFeb 24, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted95
Filer categoryAccelerated filer
Trailing twelve months to Sep 2026Revenue $379MNet income -$221MCash from operations -$190Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.